Elsevier

The Lancet

Volume 341, Issue 8848, 27 March 1993, Pages 812-813
The Lancet

VIEWPOINT
New approach for recruitment into randomised controlled trials

https://doi.org/10.1016/0140-6736(93)90573-YGet rights and content

References (7)

  • Advisory Group on Health Technology Assessment for the Director of Research and Development

    Assessing the effects of health technologies: principles, practice, proposals

    (1992)
  • Institute of Medical Ethics Working Party on the Ethical Implications of AIDS

    AIDS, ethics, and clinical trials

    BMJ

    (1992)
  • Rm Wachter

    AIDS, activism and the politics of health

    N Engl J Med

    (1992)
There are more references available in the full text version of this article.

Cited by (50)

  • Impact of a cancer clinical trials web site on discussions about trial participation: A cluster randomized trial

    2012, Annals of Oncology
    Citation Excerpt :

    The scores are comparable with other published studies and are consistent with poor knowledge about randomized clinical trials [20, 24]. In 1993, Baum called for a way to better inform people about randomized trials and it is clear that > 15 years later public and patient education is urgently required [27]. The mean decision conflict score was similar in both groups.

  • Clinical trials - A brave new partnership: A new doctor-patient working relationship in research

    2008, International Journal of Surgery
    Citation Excerpt :

    He relished dissent within the scientific process, for, as he said, “without dissent there can be no progress.” He pushed the boundaries with his 1993 Lancet paper “new approach for recruitment to randomised trials”17: this was met with excitement in my editorial commentary, but also with robust challenge.18 It led on to organised, productive, brave new partnerships in research, not just in breast cancer,19 but also generally.

  • Barriers to participation in clinical trials of cancer: A meta-analysis and systematic review of patient-reported factors

    2006, Lancet Oncology
    Citation Excerpt :

    Although the balance between societal benefits and individual patient benefits must be recognised, it seems appropriate to stress in particular the advances from clinical research with individual participants and the communities in which these studies are done.25,26 This contentious issue for ethicists and trialists is one that an institutional review board should be aware of because some critics have construed the potential societal benefit as coercion.44 In addition to the aim of easing participant anxieties, an approach that focuses on the individual patient might negate concerns related to mistrust of the scientific community and the research process in general.45

View all citing articles on Scopus
View full text